Protection of hematopoietic cells against combined O6-benzylguanine and chloroethylnitrosourea treatment by mutant forms of O6-methylguanine DNA methyltransferase

D. A. Williams, R. Maze, C. Kurpad, A. Pegg, L. C. Erickson

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

This report demonstrates that expression of the P140A O6-methylguanine DNA methyl transferase (MGMT) mutant via retrovirus-mediated gene transfer leads to significant, but modest, resistance of cells to both 6-benzylguanine (6-BG) depletion and treatment with 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU). Expression of the P140A/G156A double mutant appeared to be associated with reduced or unstable protein in hematopoietic cells. Bone Marrow Transplantation (2000) 25, Suppl. 2, S105–S109.

Original languageEnglish (US)
Pages (from-to)S105-S109
JournalBone Marrow Transplantation
Volume25
DOIs
StatePublished - May 2000

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Fingerprint

Dive into the research topics of 'Protection of hematopoietic cells against combined O<sup>6</sup>-benzylguanine and chloroethylnitrosourea treatment by mutant forms of O<sup>6</sup>-methylguanine DNA methyltransferase'. Together they form a unique fingerprint.

Cite this